Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Immunome's Varegacestat Shows Promise in Phase III Desmoid Tumor Trial

Immunome's Varegacestat Shows Promise in Phase III Desmoid Tumor Trial

Immunome, a Washington-based pharmaceutical company, has announced groundbreaking results from its Phase III RINGSIDE trial for varegacestat, a potential new treatment for desmoid tumors. The oral, once-daily gamma secretase inhibitor (GSI) demonstrated significant efficacy in improving progression-free survival and meeting all key secondary endpoints, positioning it as a strong contender for FDA approval.

NoahAI News12/16/2025
Sanofi Expands Partnership with Dren Bio in $1.7B Autoimmune Disease Deal

Sanofi Expands Partnership with Dren Bio in $1.7B Autoimmune Disease Deal

Sanofi, the French pharmaceutical giant, has once again tapped Dren Bio for a significant collaboration, this time focusing on autoimmune diseases. The new partnership, announced on Monday, is valued at up to $1.7 billion and builds upon their existing relationship in the realm of inflammatory conditions.

NoahAI News12/16/2025
Argenyx's Vyvgart Fails Phase III Trial for Thyroid Eye Disease, Impacting Future Development Plans

Argenyx's Vyvgart Fails Phase III Trial for Thyroid Eye Disease, Impacting Future Development Plans

Argenyx, a prominent player in the pharmaceutical industry, has encountered a significant setback in its clinical development program. The company's flagship drug, Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, has unexpectedly failed in a Phase III trial for thyroid eye disease (TED), a potential $550 million market opportunity.

NoahAI News12/16/2025
Philips Expands Coronary Imaging Portfolio with SpectraWAVE Acquisition

Philips Expands Coronary Imaging Portfolio with SpectraWAVE Acquisition

Philips, a global leader in health technology, has announced its agreement to acquire SpectraWAVE, a Massachusetts-based company specializing in advanced coronary artery disease diagnosis and treatment technologies. This strategic move is set to bolster Philips' image-guided therapy capabilities and expand its offerings in the coronary intervention segment.

NoahAI News12/16/2025
Sanofi's MS Drug Tolebrutinib Faces Setbacks in Clinical Trials and Regulatory Review

Sanofi's MS Drug Tolebrutinib Faces Setbacks in Clinical Trials and Regulatory Review

Sanofi, the French pharmaceutical giant, has encountered significant challenges with its multiple sclerosis (MS) drug candidate tolebrutinib. Recent developments have cast a shadow over the drug's future, impacting both its clinical trial outcomes and regulatory approval process.

NoahAI News12/16/2025
FDA Approval of Cardamyst Marks Milestone's Entry into Commercial Market

FDA Approval of Cardamyst Marks Milestone's Entry into Commercial Market

Milestone Pharmaceuticals has achieved a significant breakthrough with the FDA's approval of Cardamyst (etripamil), a novel nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). This approval marks the company's transition from a development-stage biotech to a commercial entity, ending a long regulatory journey and introducing the first new PSVT treatment in over three decades.

NoahAI News12/16/2025
Sobi Acquires Arthrosi Therapeutics in $1.5B Deal, Expanding Gout Treatment Pipeline

Sobi Acquires Arthrosi Therapeutics in $1.5B Deal, Expanding Gout Treatment Pipeline

Swedish pharmaceutical company Sobi has announced its acquisition of California-based Arthrosi Therapeutics in a deal valued at up to $1.5 billion. The move significantly bolsters Sobi's presence in the gout treatment market and adds a promising late-stage drug candidate to its pipeline.

NoahAI News12/16/2025
J&J-Backed Link Cell Therapies Launches with $60M to Develop Next-Gen CAR-T Therapies

J&J-Backed Link Cell Therapies Launches with $60M to Develop Next-Gen CAR-T Therapies

Link Cell Therapies, a Stanford University spinout, has emerged from stealth mode with a substantial $60 million Series A financing round to advance its innovative CAR-T therapy platform. The California-based biotech aims to create more potent and precise cell therapies for a range of tumor types while minimizing damage to healthy tissues.

NoahAI News12/16/2025
Argenx Halts Vyvgart Trials for Thyroid Eye Disease, Refocuses on Other Indications

Argenx Halts Vyvgart Trials for Thyroid Eye Disease, Refocuses on Other Indications

Argenx, a prominent player in the pharmaceutical industry, has announced the discontinuation of two Phase 3 trials testing its blockbuster therapy Vyvgart for thyroid eye disease. This decision comes after an interim analysis revealed the treatment's ineffectiveness compared to placebo, marking a significant setback in the company's efforts to expand the drug's applications.

NoahAI News12/16/2025
FDA Awards J&J Priority Voucher for Groundbreaking Multiple Myeloma Treatment

FDA Awards J&J Priority Voucher for Groundbreaking Multiple Myeloma Treatment

The U.S. Food and Drug Administration (FDA) has taken an unprecedented step in granting Johnson & Johnson (J&J) a Commissioner's National Priority Voucher (CNPV) for its promising combination therapy targeting multiple myeloma. This proactive move by the agency aims to expedite the review process for what could be a game-changing treatment in the field of oncology.

NoahAI News12/16/2025
J&J's Akeega Gains Second FDA Approval for BRCA2-Mutated Prostate Cancer

J&J's Akeega Gains Second FDA Approval for BRCA2-Mutated Prostate Cancer

Johnson & Johnson's (J&J) combination therapy Akeega has received its second FDA approval, positioning it as the first precision medicine combo for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). This latest development marks a significant advancement in personalized treatment options for prostate cancer patients.

NoahAI News12/16/2025
Pfizer and Sanofi Ink Major Autoimmune Deals as 2025 Draws to a Close

Pfizer and Sanofi Ink Major Autoimmune Deals as 2025 Draws to a Close

In a flurry of year-end activity, pharmaceutical giants Pfizer and Sanofi have separately announced significant collaborations in the autoimmune disease space, potentially worth billions in future payouts. These strategic moves underscore the industry's continued focus on leveraging cutting-edge technologies to address complex autoimmune disorders.

NoahAI News12/16/2025
1234...67»